Enzyme Engineering

& Industrial Fermentation

Enzymes are widely used as biocatalysts in the production or processing of a wide range of products including food, beverages, animal feeds, detergents, pharmaceuticals and textile products. Naturally occurring enzymes are often unstable or perform sub-optimally when moved from the biological to the industrial sphere.

Therefore, since the advent of protein engineering there have been efforts to improve these enzyme properties, and even to devise enzymes with novel specificities capable of producing types or quantities of metabolites not normally achievable in natural products. Such improvements or changes can often be challenging: enzyme activity depends on specific and highly complex structures, sometimes formed from multiple protein components, and requiring associated factors or metal ions to operate. Frequently, enhancing one desirable property comes at the cost of impairing another.

Mewburn Ellis has a long history of working with our clients in this fast-moving and competitive field. For example, we’ve been involved in protecting the ground-breaking innovations on the serine protease subtilisin (used for example in detergents and in food processing) since 1980s, and in multiple other enzymes in different fields such as brewing, biofuels and biopolymers. The Mewburn team has regularly and successfully defended patents covering our clients’ enzyme technologies at the EPO and assisted them in enforcing those patents before national courts. Engineered enzymes are typically produced in host species such as bacteria, yeasts and filamentous fungi and we also have many years’ experience in dealing with the fermentation technologies used for growing these microorganisms, and recovering the enzymes from them, whether at laboratory or industrial scale.

As more and more powerful computation tools are developed for determining and modelling protein structures, so protein engineers are increasingly able to analyse the structure-function characteristics for rationale design of novel enzymes, which can then be tested in large scale functional screening processes. Once again, our specialised team here is able to assist at our clients with obtaining protection for their intellectual property in the latest bioinformatics innovations in the enzyme space.

Open pages of Green IP Report

Green IP Report

Patents are both a driver and a barometer of innovation

Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.

We share our enthusiasm and admiration for commercially-focused innovation across a diverse range of technologies, from repurposing carbon dioxide to make protein-rich foods, to the multi-faceted approach to a circular plastics economy. We also discuss the tantalising prospect of AI-mediated renewable energy supply, and the harnessing of battery tech from the EV boom to drive energy efficiency in consumer devices. This report reflects our passion for technology solutions that tackle our shared global challenge.

Download the Report

Read our Blogs

Beyond PROTACs and molecular glues: where next for heterobifunctional drug discovery?

Beyond PROTACs and molecular glues: where next for heterobifunctional drug discovery?

by Annabel Cardno

A broader heterobifunctional tool emerges Targeted protein degradation has rapidly progressed from a conceptual curiosity to one of the most closely watched areas in drug discovery. As discussed in ...

Global considerations for innovators in microbial biostimulants and biocontrol agents

Global considerations for innovators in microbial biostimulants and biocontrol agents

by Ben Tolley

Our recent analysis found that global patent activity in microbial biostimulants and biocontrol agents is surging, with strong growth in both patent applications and granted patents. For a detailed ...

EPO decision T 0655/24: inventive step and the unpredictability of antibody mutations

EPO decision T 0655/24: inventive step and the unpredictability of antibody mutations

by Chris Denison

This is the final post in a series on decision T 0655/24 and its implications for antibody practice at the EPO. In the first post, Chris discussed the Board’s strict approach to post-filing evidence ...

EU NGT Regulation Approved: A Step Towards Innovation

EU NGT Regulation Approved: A Step Towards Innovation

by Louise Atkins

The EU’s long‑awaited regulation on New Genomic Techniques (NGTs) has now cleared its final legislative hurdle, with the European Parliament voting to approve the agreed framework, rejecting ...

Molecular Glue Degraders (MGDs): what they are, how they work and key IP Issues

Molecular Glue Degraders (MGDs): what they are, how they work and key IP Issues

by Tim Nash

Molecular glue degraders (MGDs) are small molecules that induce or stabilise protein–protein interactions, often by recruiting an E3 ligase to a target protein and triggering its ubiquitination and ...

Ageing as a disease: Groundbreaking or Ground-Shaking?

Ageing as a disease: Groundbreaking or Ground-Shaking?

by Emily Garnett

As a species, humans have long been preoccupied with living longer and healthier lives. However, prior to the advent of modern medicine, any real prospect of fulfilling these ambitions existed more ...

Learn More
ME Forward Masthead White 2